Bridgeway Capital Management Inc. grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 312,500 shares of the medical research company’s stock after buying an additional 7,500 shares during the period. Bridgeway Capital Management Inc.’s holdings in Amgen were worth $64,778,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Mutual Advisors LLC boosted its holdings in shares of Amgen by 5.8% during the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after buying an additional 265 shares in the last quarter. Lederer & Associates Investment Counsel CA boosted its holdings in shares of Amgen by 2.4% during the 3rd quarter. Lederer & Associates Investment Counsel CA now owns 13,150 shares of the medical research company’s stock valued at $2,726,000 after buying an additional 310 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Amgen by 2.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after buying an additional 72,205 shares in the last quarter. Argent Trust Co boosted its holdings in shares of Amgen by 31.8% during the 2nd quarter. Argent Trust Co now owns 11,691 shares of the medical research company’s stock valued at $2,159,000 after buying an additional 2,818 shares in the last quarter. Finally, Lau Associates LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $406,000. Hedge funds and other institutional investors own 76.94% of the company’s stock.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the transaction, the senior vice president now owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.19% of the stock is currently owned by insiders.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The business had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. During the same quarter in the previous year, the firm earned $3.27 EPS. Amgen’s revenue was up 2.3% on a year-over-year basis. Sell-side analysts forecast that Amgen, Inc. will post 14.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is 41.97%.
Several equities analysts have recently issued reports on AMGN shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $220.00 price target on shares of Amgen in a research report on Friday, August 24th. Oppenheimer reaffirmed a “buy” rating and issued a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Wells Fargo & Co reaffirmed a “neutral” rating and issued a $197.00 price target on shares of Amgen in a research report on Wednesday, August 29th. Royal Bank of Canada reaffirmed a “neutral” rating and issued a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Finally, Leerink Swann set a $209.00 price target on Amgen and gave the stock a “hold” rating in a research report on Monday, September 17th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $205.68.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: How much money do you need to begin day trading?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.